In all publications and presentations resulting from this trial, patients’ anonymity will be protected to the maximum extent possible. Authorized personnel from the National Cancer Institute (NCI) and Food and Drug Administration (FDA) or other regulatory authorities may have access to research files in order to verify that patients’ rights have been safeguarded. 12.4.1 Known Potential Risks  Research Blood Collection Risks of blood draws include pain and bruising in the area where the needle is placed, lightheadedness, and rarely, fainting. When large amounts of blood are collected, low red blood cell count (anemia) can develop.  Tumor, normal mucosa and skin biopsies Risks of tumor biopsy include bleeding, minor discomfort, and infection. Risk of bleeding will be minimized with the use of lidocaine with epinephrine local anesthesia and the conservative use of electrocautery (if in the operating room) or silver nitrate (if in the clinic). Discomfort is not a concern if the patient is under general anesthesia and with be minimized in the clinic with the use of injectable local anesthetic per standard-of-care approaches. Risk of injection with biopsies is minimal, but short course of oral antibiotics after biopsies may be provided at the discretion of the investigator. Biopsies of tumor and normal mucosa will be performed with sterilized 1-3 mm cupped biopsy forceps. Skin biopsies will be obtained with 2-4 mm punch biopsies. For skin biopsies, edges of wound will be approximated with suture using sterile, standard of care technique. Suture closure is not required for tumor or normal mucosal biopsies. In addition to the risks detailed in the consent for associated with this protocol, patients will be consented for all tumor, normal mucosa and skin tissue biopsies with a clinical consent form for either operative intervention under general anesthesia or for clinic-based procedures under local anesthesia.  Risks of the study agents Risks include the possible occurrence of any of a range of side effects which are listed in the Consent Document or this protocol document. Frequent monitoring for adverse effects will help to minimize the risks associated with administration of the study agents.  Risks due to contrast dye used in CT scans If contrast dye is used, there is a risk for allergic reaction to the dye. Patients who are allergic to or sensitive to medications, contrast dye, iodine, or shellfish should notify their physician.